Effects of C-reactive protein on adipokines genes expression in 3T3-L1 adipocytes

Biochemical and Biophysical Research Communications

Volumn 424, Issue 3, 2012, Pages 462-468

  Yuan, Guoyue ^a   Jia, Jue ^a   Di, Liangliang ^a   Zhou, Libin ^b   Dong, Sijing ^a   Ye, Jingjing ^a   Wang, Dong ^a   Yang, Ling ^a   Wang, Jifang ^a   Li, Lianxi ^c   Yang, Ying ^b   Mao, Chaoming ^a   Chen, Mingdao ^b  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

3T3 L1 adipocyte; Adipokines; C reactive protein (CRP); Interleukin 6 (IL 6); Tumor necrosis factor (TNF )

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN;

ADIPOCYTE; ARTICLE; CELL MATURATION; CELL STRAIN 3T3; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPOKINES; ANDROSTADIENES; ANIMALS; C-REACTIVE PROTEIN; GENE EXPRESSION; GENE EXPRESSION REGULATION; MICE; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84864779102     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.133     Document Type: Article

References (43)

1. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
2. Lee S., Kim I.T., Park H.B., Hyun Y.K., Kim Y.J., Song S.O., Kim H. High-sensitivity C-reactive protein can predict major adverse cardiovascular events in korean patients with type 2 diabetes. J. Korean Med. Sci. 2011, 26(10):1322-1327.
3. Festa A.D., Agostino R., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51(4):1131-1137.
4. Indulekha K., Surendar J., Mohan V. High sensitivity C-reactive protein, tumor necrosis factor-α, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). J. Diabetes Sci. Technol. 2011, 5(4):982-988.
5. Aronson D., Bartha P., Zinder O., Kerner A., Shitman E., Markiewicz W., Brook G.J., Levy Y. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet. Med. 2004, 21:39-44.
6. Bremer A.A., Devaraj S., Afify A., Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96(11):1782-1788.
7. Schulze M.B., Rimm E.B., Shai I., Rifai N., Hu F.B. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004, 27(7):1680-1687.
8. Yuan G., Zhou L., Tang J., Yang Y., Gu W., Li F., Hong J., Gu Y., Li X., Ning G., Chen M. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res. Clin. Pract. 2006, 72(3):244-250.
9. Lyon C.J., Law R.E., Hsueh W.A., Chaldakov G.N., Stankulov I.S., Hristova M., Ghenev P.I. Minireview: adiposity inflammation, and atherogenesis. Endocrinology 2003, 144(6):2195-2200.
10. Conde J., Scotece M., Gómez R., López V., Gómez-Reino J.J., Lago F., Gualillo O. A complex hub among inflammation, metabolism, and immunity. BioFactors 2011, 37(6):413-420.
11. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27(3):813-823.
12. Trujillo M.E., Scherer P.E. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev. 2006, 27(7):762-778.
13. Mirza S., Hossain M., Mathews C., Martinez P., Pino P., Gay J.L., Rentfro A., McCormick J.B., Fisher-Hoch S.P. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine 2011, 57(1):136-142.
14. Fei H., Okano H.J., Li C., Lee G.H., Zhao C., Darnell R., Friedman J.M. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc. Natl. Acad. Sci. USA 1997, 94(13):7001-7005.
15. Bjorbaek C., Kahn B.B. Leptin signaling in the central nervous system and the periphery. Recent Prog. Horm. Res. 2004, 59:305-331.
16. Baban R.S., Kasar K.A., Al-Karawi I.N. Fasting glucose to leptin ratio as a new diagnostic marker in patients with diabetes mellitus. Oman Med. J. 2010, 25(4):269-275.
17. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13(2):84-89.
18. Aprahamian T.R., Sam F. Adiponectin in cardiovascular inflammation and obesity. Int. J. Inflamm. 2011, 1-8.
19. Schmidt B.B., Knethen A.V. TThe nuclear hormone receptor PPARγ as a therapeutic target in major diseases. Scientific World J. 2010, 10:2181-2197.
20. Spiegelman B.M., Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell 1996, 87(3):377-389.
21. Yuan G., Chen X., Ma Q., Qiao J., Li R., Li X., Li S., Tang J., Zhou L., Song H., Chen M. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J. Endocrinol. 2007, 194(2):275-281.
22. Dehoux M.J., van Beneden R.P., Fernández-Celemín L., Lause P.L., Thissen J.P. Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett. 2003, 544(1-3):214-217.
23. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., Kihara S., Funahashi T., Tenner A.J., Tomiyama Y., Matsuzawa Y. Adiponectin, a newmember of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96(5):1723-1732.
24. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001, 7(8):941-946.
25. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., Tataranni P.A. Hypoadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001, 86(5):1930-1935.
26. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., Knowler W.C., Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360(9326):57-58.
27. Hotamisligil G.S., Arner P., Atkinson R.L., Spiegelman B.M. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 1997, 46(3):451-455.
28. Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin resistant subjects. J. Biol. Chem. 2003, 278(46):45777-45784.
29. Kaneko H., Anzai T., Nagai T., Anzai A., Takahashi T., Mano Y., Morimoto K., Maekawa Y., Itoh H., Yoshikawa T., Ogawa S., Fukuda K. Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. Cardiovasc. Res. 2011, 91(3):546-555.
30. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148(2):209-214.
31. Devaraj S., Torok N., Dasu M.R., Samols D., Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler. Thromb. Vasc. Biol. 2008, 28(7):1368-1374.
32. Sun H., Zhang Y., Gao P., Li Q., Sun Y., Zhang J., Xu C. Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells. Mol. Cell. Biochem. 2011, 347(1-2):183-189.
33. Rosen E.D., Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444(7121):847-853.
34. Schwartz M.W., Baskin D.G., Bukowski T.R., Kuijper J.L., Foster D., Lasser G., Prunkard D.E., Porte D., Woods S.C., Seeley R.J., Weigle D.S. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996, 45(4):531-535.
35. Farooqi I.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., Sanna V., Jebb S.A., Perna F., Fontana S., Lechler R.I., DePaoli A.M., O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 2002, 110(8):1093-1103.
36. Oral E.A., Simha V., Ruiz E., Andewelt A., Premkumar A., Snell P., Wagner A.J., DePaoli A.M., Reitman M.L., Taylor S.I., Gorden P., Garg A. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 2002, 346(8):570-578.
37. Széles L., Töröcsik D., Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim. Biophys. Acta 2007, 1771(8):1014-1030.
38. Marnell L., Mold C., Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 2005, 117(2):104-111.
39. Garcia-Macedo R., Sanchez-Munoz F., Almanza-Perez J.C., Duran-Reyes G., Alarcon-Aguilar F., Cruz M. Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur. J. Pharmacol. 2008, 587:317-321.
40. Ajuwon K.M., Spurlock M.E. Adiponectin inhibits LPS-induced NF-kappa B activation and IL-6 production and increases PPARγ2 expression in adipocytes. Am. J. Physiol. Regul. 2005, 288:1220-1225.
41. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., Christian J.A., Spurlock M.E. Adiponectin differentially regulated cytokines in porcine macrophages. Biochem. Biophys. Res. Commun. 2004, 316(3):924-929.
42. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003, 301:1045-1050.
43. Gustafson B., Jack M.M., Cushman S.W., Smith U. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem. Biophys. Res. Commun. 2003, 308(4):933-939.